title: [Efficacy comparison of combined intracoronary administration of high-dose adenosine and tirofiban versus intracoronary tirofiban during primary percutaneous coronary intervention in patients with acute myocardial infarction].
abstract: OBJECTIVE
  To compare the efficacy of intracoronary administration of combined high-dose adenosine and tirofiban versus intracoronary tirofiban during primary percutaneous coronary intervention (PCI) in patients with acute myocardial infarction.
  
  
  METHODS
  Consecutive 258 patients with acute ST-segment elevation myocardial infarction (STEMI) underwent primary PCI, treated with thrombus aspiration and then intracoronary tirofiban, were randomly divided into adenosine group (n = 130) and control group (n = 128). Adenosine group received 2 times intracoronary adenosine (2 mg) after thrombus aspiration and after stenting of the infarct-related artery through the aspiration catheter. Control group received placebo. The primary end point was myocardial blush grade (MBG) after PCI. Secondary end points were thrombolysis in myocardial infarction (TIMI) flow grade and corrected TIMI frame count (CTFC) after PCI, ST-segment elevation resolution (STR), and major adverse cardiac events (MACE) at 30 days and 12 months.
  
  
  RESULTS
  TIMI flow grade post PCI did not differ between the 2 groups, while CTFC favored the adenosine-treated patients [(21.6 ± 6.5) frames] compared with the placebo-treated patients [(25.1 ± 7.8) frames, P = 0.001]. MBG 3 was more frequently observed in the adenosine compared to the control group [45.1% (55/122) vs.32.0% (39/122), P = 0.035]. Patients in the adenosine group had a trend of higher rate of compete STR after the procedure compared patients in the control group [53.6% (67/125) vs. 41.9% (52/124), P = 0.065]. The incidence of MACE was comparable between patients randomized to adenosine and placebo at 30 days [12.3% (16/130) vs. 17.2% (22/128), P = 0.295] and at 12 months [12.3% (16/130) vs. 18.0% (23/128), P = 0.227].
  
  
  CONCLUSIONS
  Intracoronary administration of high-dose adenosine combined with tirofiban provides further improvement on myocardial perfusion after primary PCI but does not affect the clinical outcomes in patients with STEMI.
authors.affiliation: Heart Center, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100043, China.
authors.forename: Zi-chuan
authors.initials: ZC
authors.lastname: Tong
authors.affiliation: Heart Center, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100043, China.
authors.forename: Qiang
authors.initials: Q
authors.lastname: Li
authors.affiliation: Heart Center, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100043, China.
authors.forename: Ming
authors.initials: M
authors.lastname: Chen
authors.affiliation: Heart Center, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100043, China.
authors.forename: Guo-bin
authors.initials: GB
authors.lastname: Miao
authors.affiliation: Heart Center, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100043, China.
authors.forename: Yu
authors.initials: Y
authors.lastname: Wei
authors.affiliation: Heart Center, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100043, China.
authors.forename: Fei-ou
authors.initials: FO
authors.lastname: Li
authors.affiliation: Heart Center, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100043, China.
authors.forename: Hua
authors.initials: H
authors.lastname: Zhao
authors.affiliation: Heart Center, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100043, China. Email: zmn0359@vip.sina.com.
authors.forename: Jian-jun
authors.initials: JJ
authors.lastname: Zhang
mesh_terms: D000241:Adenosine / Q000627:therapeutic use*; D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000628:therapy*; D062645:Percutaneous Coronary Intervention; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D000077466:Tirofiban; D014443:Tyrosine / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D010975:Platelet Aggregation Inhibitors; D014443:Tyrosine; D000077466:Tirofiban; D000241:Adenosine